About TOLREMO therapeutics
TOLREMO therapeutics is a company based in Zurich (Switzerland) founded in 2017 by Karl-Heinz Altmann, Emmanuel Savioz, Wilhelm Krek, Isaac Kobrin, and Stefanie Fluckiger-Mangual.. TOLREMO therapeutics has raised $55.81 million across 4 funding rounds from investors including Zurcher Kantonalbank, BioMedPartners and Altos Ventures Management. TOLREMO therapeutics offers products and services including TT125-802. TOLREMO therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Zurich, Switzerland
- Founders Karl-Heinz Altmann, Emmanuel Savioz, Wilhelm Krek, Isaac Kobrin, Stefanie Fluckiger-Mangual
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tolremo Therapeutics Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$55.81 M (USD)
in 4 rounds
-
Latest Funding Round
$39 M (USD), Series A
Sep 20, 2023
-
Investors
Zurcher Kantonalbank
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TOLREMO therapeutics
TOLREMO therapeutics offers a comprehensive portfolio of products and services, including TT125-802. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits transcriptional resistance in cancer cells to enhance targeted therapies.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of TOLREMO therapeutics
TOLREMO therapeutics has successfully raised a total of $55.81M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $39 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $39.0M
-
First Round
First Round
(18 Sep 2017)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Series A - TOLREMO therapeutics | Valuation | BioMedPartners |
|
| Jun, 2020 | Amount | Series A - TOLREMO therapeutics | Valuation | BioMedPartners , Altos Ventures Management | |
| Sep, 2018 | Amount | Series A - TOLREMO therapeutics | Valuation | BioMedPartners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TOLREMO therapeutics
TOLREMO therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Zurcher Kantonalbank, BioMedPartners and Altos Ventures Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
|
Founded Year | Domain | Location | |
|
Early-stage companies are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Early-stage investments are directed toward ICT and health tech startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TOLREMO therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TOLREMO therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tolremo Therapeutics Comparisons
Competitors of TOLREMO therapeutics
TOLREMO therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tolremo Therapeutics
Frequently Asked Questions about TOLREMO therapeutics
When was TOLREMO therapeutics founded?
TOLREMO therapeutics was founded in 2017.
Where is TOLREMO therapeutics located?
TOLREMO therapeutics is headquartered in Zurich, Switzerland.
Who is the current CEO of TOLREMO therapeutics?
Stefanie Fluckiger-Mangual is the current CEO of TOLREMO therapeutics. They have also founded this company.
Is TOLREMO therapeutics a funded company?
TOLREMO therapeutics is a funded company, having raised a total of $55.81M across 4 funding rounds to date. The company's 1st funding round was a Series A of $9.38M, raised on Sep 18, 2017.
What does TOLREMO therapeutics do?
TOLREMO therapeutics was founded in 2017 in Zurich, Switzerland, within the biotechnology sector. Small molecules are developed by the company to address novel drug resistance pathways in cancer. A screening platform is utilized for identifying anti-drug resistance cancer therapies. Existing drugs are also combined to mitigate resistance development. Operations focus on oncology research and therapeutic innovation.
Who are the top competitors of TOLREMO therapeutics?
TOLREMO therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does TOLREMO therapeutics offer?
TOLREMO therapeutics offers TT125-802.
Who are TOLREMO therapeutics's investors?
TOLREMO therapeutics has 4 investors. Key investors include Zurcher Kantonalbank, BioMedPartners, Altos Ventures Management, and Redalpine.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.